°ÐÏò¶¨Á¿µ°°×ÖÊ×éѧ¼¼Êõ£¬Êdzä·ÖÀûÓÃÖÊÆ×ÒDZ¾ÉíµÄÌØÐÔ£¬¶Ô½øÈëÖÊÆ×µÄÀë×Ó½øÐжà´ÎɸÑ¡£¬½ø¶ø°ÐÏòÑ¡¶¨Ä¿±êµ°°×¶àëĵÄËéÁÑÀë×Ó£¬½øÐж¨Ïò¼ì²âµÄÖÊÆ×¼¼Êõ¡£ Ä¿Ç°£¬Ëæ×Å°ÐÏò¶¨Á¿µ°°×ÖÊ×éѧ¼¼ÊõµÄ·¢Õ¹£¬Ö÷Òª·¢Õ¹ÎªMRM£¨¶à·´Ó¦¼à²â£¬Multiple Reaction Monitoring£©ºÍPRM£¨Æ½Ðз´Ó¦¼à²â£¬Parallel Reaction Monitoring£©Á½ÖÖ¼¼Êõ·Ïß¡£

 

 

 

|   MRM°ÐÏòµ°°×Öʶ¨Á¿·ÖÎö

       MRM¼¼ÊõÊÇÀûÓÃÈýÖØËļ¶¸ËÖÊÆ×¼¼Êõ£¨QQQ£©µÄ¶¨ÐÔ¶àÖØÀë×ÓɸѡÄÜÁ¦£¬¿ª·¢³öµÄ¶Ô¸´ÔÓÑùÆ·Öжà¸öÌض¨µ°°×/ëĶÎ/ С·Ö×Ó½øÐаÐÏò¶¨Á¿·ÖÎöµÄ¼¼Êõ¡£Q1 ɸѡ³öÓëÄ¿±ê·Ö×ÓÌØÒìÐÔÒ»ÖµÄĸÀë×Ó£»Q2 ÅöײËéÁÑÕâЩĸÀë×Ó£¬È¥³ýÆäËüÀë×Ó¸ÉÈÅ£»Q3 Ö»¶ÔÑ¡¶¨µÄMS2 Àë×Ó¶Ô½øÐÐÖÊÆ×ÐźŲɼ¯£¬Íê³É°ÐÏò¶¨Á¿¡£½èÖúͬλËرê¼ÇµÄÄ¿±êëĶΣ¬MRM »¹¿ÉʵÏÖµ°°×Öʵľø¶Ô¶¨Á¿¡£

|   MRM°ÐÏòµ°°×Öʶ¨Á¿·ÖÎö

       MRM¼¼ÊõÊÇÀûÓÃÈýÖØËļ¶¸ËÖÊÆ×¼¼Êõ£¨QQQ£©µÄ¶¨ÐÔ¶àÖØÀë×ÓɸѡÄÜÁ¦£¬¿ª·¢³öµÄ¶Ô¸´ÔÓÑùÆ·Öжà¸öÌض¨µ°°×/ëĶÎ/ С·Ö×Ó½øÐаÐÏò¶¨Á¿·ÖÎöµÄ¼¼Êõ¡£Q1 ɸѡ³öÓëÄ¿±ê·Ö×ÓÌØÒìÐÔÒ»ÖµÄĸÀë×Ó£»Q2 ÅöײËéÁÑÕâЩĸÀë×Ó£¬È¥³ýÆäËüÀë×Ó¸ÉÈÅ£»Q3 Ö»¶ÔÑ¡¶¨µÄMS2 Àë×Ó¶Ô½øÐÐÖÊÆ×ÐźŲɼ¯£¬Íê³É°ÐÏò¶¨Á¿¡£½èÖúͬλËرê¼ÇµÄÄ¿±êëĶΣ¬MRM »¹¿ÉʵÏÖµ°°×Öʵľø¶Ô¶¨Á¿¡£

|   PRM°ÐÏòµ°°×Öʶ¨Á¿·ÖÎö

       PRMÊÇÒÀÀµÓڸ߷ֱæ/ ¸ß¾«¶ÈÖÊÆ×ÒÇ£¨ÓÈÆäÊÇobitrapϵÁУ©µÄ¸ß·Ö±æÂʵÄÓÅÊƶø¿ª·¢µÄ°ÐÏò¶¨Á¿µ°°×ÖÊ·ÖÎö¼¼Êõ£¬ÆäÓŵãÊÇÎÞÐèÊÂÏÈÈ·¶¨Àë×Ó¶ÔºÍÓÅ»¯ÅöײÄÜÁ¿£¬²Ù×÷¼ò±ã£¬ÊÇMRM µÄÑÜÉú¼¼Êõ¡£Ê×ÏÈ£¬ÀûÓÃËļ¶¸ËÖÊÁ¿·ÖÎöÆ÷Ñ¡ÔñÐԵؼì²âÄ¿±êëĶεÄĸÀë×Ó£»ËæºóÔÚCollision cell ÖжÔĸÀë×Ó½øÐÐËéÁÑ£»×îºóÀûÓÃOrbitrap ·ÖÎöÆ÷ÔÚ¶þ¼¶ÖÊÆ×Öмì²âËùÑ¡ÔñµÄĸÀë×Ó´°¿ÚÄÚµÄËùÓÐËéƬÐÅÏ¢£¬¶ÔÄ¿±êµ°°×/ ëĶνøÐж¨Á¿·ÖÎö¡£

|   ¼¼Êõ±È½Ï

       ÎÞÂÛMRM»¹ÊÇPRM¾ù¿É½ÏºÃµÄ¶Ô·Ç°ÐÏòµ°°×ÖÊ×éɸѡµÄÊý¾Ý½øÐаÐÏò¶¨Á¿¼ì²â£¬ÓÉÓÚÁ½ÖÖ¼¼Êõ¿ª·¢µÄÔ­ÀíºÍÒÀÍеÄÒÇÆ÷ƽ̨²»Í¬¡£Òò´Ë£¬Á½ÖÖ¼¼ÊõµÄ¼ì²âÌصãºÍ¾ßÌåÓ¦Óþù¾ßÓÐÒ»¶¨µÄ²îÒì¡£

       MRMÊÇÔÚ°ÐÏò·Ö×Ó¼ì²âµÄרÓÃƽ̨ÈýÖØËļ¶¸Ë»ù´¡ÉÏ¿ª·¢µÄ°ÐÏò´ó·Ö×Óµ°°×Öʼì²â¼¼Êõ£¬ÆäÌصãÊǼì²âËٶȿ죬Àë×ÓɸѡÄÜÁ¦Ç¿£¬²¢ÇÒÅäÌ×µÄÊÇ΢ÉýÒºÏàϵͳ£¬ÒÇÆ÷Îȶ¨ÐԺ㬶¨Á¿×¼È·ÐԸߡ£MRM¼¼ÊõÓÈÆäÊʺ϶ÔÌض¨Ð¡ÈºÄ¿±êµ°°×½øÐдóÅúÁ¿Ñù±¾µÄ¶¨Á¿¼ì²â£¨ÓÈÆäÊÇÁÙ´²´ó¶ÓÁÐÑù±¾£©¡£

       PRMÊÇÒÀÍÐÖÊÆ×Òǵĸ߷ֱæÂÊÐÔÄÜ¿ª·¢µÄ°ÐÏò´ó·Ö×Óµ°°×Öʼì²â¼¼Êõ£¬ÆäÌصãÊǵ°°××éµÄɸѡºÍÑéÖ¤¿ÉÒÔÔÚһ̨ÖÊÆ×ÒÇÉÏʵÏÖ£¬²Ù×÷¼ò±ã£¬¼ì²â³É±¾µÍ£¬¿É°ÐÏò¼à²âµÄÀë×ÓÊýÁ¿¶à¡£µ«ÊÇÓÉÓÚÅäÌ×µÄÊÇÄÉÉýÒºÏàϵͳ£¬ÆäÒÇÆ÷µÄÎȶ¨ÐԽϲîһЩ¡£Òò´Ë£¬Ò»°ãÊÇÔÚ·Ç°ÐÏòµ°°×ÖÊ×éѧÍê³Éºó¶ÌʱÆÚÄÚ£¬ÔÚÖÊÆ×ÒǽøÐÐÏÂÒ»ÂÖά»¤Ö®Ç°Íê³ÉPRMʵÑé¡£PRM¼¼ÊõÊʺÏСÅúÁ¿Ñù±¾£¬½Ï¶àÄ¿±êµ°°×°ÐÏò¶¨Á¿¼ì²âµÄʵÑéÐèÇó¡£

|   ¾­µä°¸Àý

       ¸ÃÎÄÏױȽÏÁËËÄÖÖµ°°×ÖÊ×éѧ·½·¨£¨DDA¡¢DIA¡¢PRM¡¢MRM£©µÄÐÔÄÜ¡£ÊµÑéÁ÷³ÌÈçÏÂͼ£¬È¡À´×ÔÈýÃûÅ·ÖÞÈ˺ÍÁ½Ãû·ÇÖÞÈ˵ĵ¥¸öÈËÀàë¸É£¨hair shafts£©½øÐÐÏû»¯,´ÓJPT Peptide Technologie¹«Ë¾»ñµÃ24ÌõÒÅ´«±äÒìëÄ£¨GVP£¬genetically variant peptides£©²¢½«ËüÃÇ»ìºÏºóÌí¼Óµ½ÎåÃûÊÜÊÔÕßµÄÈËÀàë¸Éµ°°×ÈÜÒºÖУ¬²ÉÓÃQE plus-DDA¡¢Lumos-DIA¡¢Lumos-PRM¡¢QQQ-MRM½øÐзÖÎö¡£

       Í¨¹ý¶ÔËĸö·ÖÎöƽ̨µÄÐÔÄܽøÐÐÆÀ¹À£¬Ñ¡È¡24ÌõëĶÎÖеÄ3Ìõ½øÐзÖÎö£¬·¢ÏÖµÚÒ»ÌõëĶÎDSQECILMETEARÔÚLumos-DIA ÖÐȱÉÙ£¬µÚ¶þÌõëĶÎGILIDTSRÔÚQE plus-DDAÖÐȱÉÙ£¬µÚÈýÌõëĶÎLEGEINMYRÔÚQE plus-DDAºÍLumos-PRMÖоùȱÉÙ¡£×ÜÖ®ÕâÈýÌõëĶÎMRM¾ùÄܼì³ö£¬¶øPRMÖ»Äܼì³öÆäÖеÄÁ½Ìõ¡£

       ½øÒ»²½¶ÔËĸö·ÖÎöƽ̨µÄÐÔÄܽøÐÐ×ÛºÏÐÔÄÜÆÀ¹À£¬·¢ÏÖQE plus-DDAµÄ¼ø¶¨°Ù·Ö±ÈΪ26.4%£¬¼ì²âÁéÃô¶ÈΪ43.2%£¬´íÎó·¢ÏÖÂÊ(FDR)×îµÍ£¬Îª2.6%¡£Lumos-DIAµÄ¼ø¶¨°Ù·Ö±ÈΪ13.2%£¬¼ì²âÁéÃô¶ÈΪ21.6%£¬FDRΪ5.0%£¬Lumos-PRMµÄ¼ø¶¨°Ù·Ö±ÈΪ33.3%£¬¼ì²âÁéÃô¶ÈΪ 54.5%£¬FDRÒ²×î¸ß£¬Îª12.7%¡£QQQ-MRMµÄ¼ø¶¨°Ù·Ö±ÈΪ42.4%£¬¼ì²âÁéÃô¶ÈΪ69.3%£¬FDRΪ4.7%¡£

       ×ÜÌå¶øÑÔ£¬ÓëDIAÏà±È£¬Ó¦ÓÃÓÚPRMʹ¼ì²âÁéÃô¶ÈÌá¸ßÁË1.3±¶£¬MRMʹ¼ì²âÁéÃô¶ÈÌá¸ßÁË1.6±¶¡£ÓëPRMÏà±È£¬MRMµÄ¼ì²âÁéÃô¶È½Ï¸ß£¬Í¬Ê±ÔÚFDRÉÏ£¬±ÈPRMµÍ¡£

|   Ïà¹ØÎÄÏ×

[1]. Zachary C Goecker, Kevin M Legg, Michelle R Salemi, et al. Alternative LC-MS/MS Platforms and Data Acquisition Strategies for Proteomic Genotyping of Human Hair Shafts. J Proteome Res. 2021 Oct 1;20(10):4655-4666. 

[2]. Peggy Barschke, Patrick Oeckl, Petra Steinacker, et al. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. J Neurol Neurosurg Psychiatry. 2020 May;91(5):503-511.

[3]. Megha Bhardwaj, Korbinian Weigl, Kaja Tikk, et al. Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer. Eur J Cancer. 2020 Mar;127:30-40.

[4]. Patrick Oeckl, Patrick Weydt, Dietmar R Thal, et al. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020 Jan;139(1):119-134.

[5]. Gerard A Silvestri, Nichole T Tanner, Paul Kearney, et al. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. Chest. 2018 Sep;154(3):491-500. 

[6]. Anil Vachani, Harvey I Pass, William N Rom, et al. Validation of a Multiprotein Plasma Classifier to Identify Benign Lung Nodules. J Thorac Oncol. 2015 Apr;10(4):629-37.